Ginkgo Bioworks and the Rwanda Biomedical Centre announced a one-year pathogen monitoring program at Rwanda’s Kigali International Airport to identify new and emerging variants of SARS-CoV-2.
The program establishes a new node in a global early warning network for emerging variants to support timely and targeted public health response
BOSTON and KIGALI, Rwanda, Feb. 15, 2023 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, and the Rwanda Biomedical Centre (RBC) today announced a one-year pathogen monitoring program at Rwanda’s Kigali International Airport (KGL) to identify new and emerging variants of SARS-CoV-2.
Through this program, Ginkgo’s biosecurity and public health unit, Concentric by Ginkgo, will collaborate with RBC to monitor wastewater samples from arriving aircraft and nasal swab samples, collected on a voluntary, anonymous basis from arriving international travelers, for SARS-CoV-2. The program aims to provide critical public health insights to help inform mitigation strategies in Rwanda and globally.
Ginkgo and RBC will work together to establish KGL as a new node in a global network of pathogen monitoring infrastructure, complementing the insights generated from Concentric’s existing travel biosecurity programs at several major international airports in the U.S. The program builds on Ginkgo’s previously announced MOU to develop and implement biosecurity capabilities in Rwanda.
“Mitigating the risk of biological threats, including emerging viral variants, remains a global imperative that necessitates a robust early warning system,” stated Matt McKnight, General Manager, Biosecurity at Ginkgo Bioworks. “This pathogen monitoring program at Kigali International Airport will act like a public health radar, providing leaders with near-real-time data to inform targeted response strategies. We are excited to be partnering with the Rwanda Biomedical Centre—to stay ahead of the next variant or pathogen of concern, we must take an international approach to biosecurity.”
RBC is Rwanda’s national health implementation agency, established in 2011 to improve the health of the Rwandan population by providing high quality, affordable and sustainable health care services. Ginkgo will support the end-to-end collection and analysis workflow with materials, training and logistical support, digital platform and data reporting, as well as bioinformatics and decision support services; RBC will contribute on-the-ground operational support for sample collection, testing, and sequencing.
Prof. Claude Muvunyi, the Director General of the Rwanda Biomedical Centre said, “As we continue to feel the impacts of emerging variants and pathogens, we recognize the need to create a sustainable public health and biosecurity infrastructure in Rwanda and internationally. We are thrilled to launch this program at Kigali International Airport in partnership with Ginkgo to enhance our biosecurity capabilities.”
About Ginkgo Bioworks
Ginkgo Bioworks is the leading horizontal platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. Ginkgo’s biosecurity and public health unit, Concentric by Ginkgo, is building global infrastructure for biosecurity to empower governments, communities, and public health leaders to prevent, detect and respond to a wide variety of biological threats. For more information, visit ginkgobioworks.com and concentricbyginkgo.com, read our blog, or follow us on social media channels such as Twitter (@Ginkgo and @ConcentricByGBW), Instagram (@GinkgoBioworks and @ConcentricByGinkgo), or LinkedIn.
About Rwanda Biomedical Centre
The Rwanda Biomedical Centre (RBC) is a data and science-driven health implementing agency in Rwanda that leads and coordinates essential public health functions under the Ministry of Health.
Forward-Looking Statements of Ginkgo Bioworks
This press release contains certain forward-looking statements within the meaning of the federal securities laws, including statements regarding the potential success of the partnership and Ginkgo’s biosecurity platform. These forward-looking statements generally are identified by the words “believe,” “can,” “project,” “potential,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to:(i) volatility in the price of Ginkgo’s securities due to a variety of factors, including changes in the competitive and highly regulated industries in which Ginkgo operates and plans to operate, variations in performance across competitors, and changes in laws and regulations affecting Ginkgo’s business, (ii) the ability to implement business plans, forecasts, and other expectations, and to identify and realize additional business opportunities, (iii) the risk of downturns in demand for products using synthetic biology, (iv) the unpredictability of the duration of the COVID-19 pandemic and the demand for COVID-19 testing and the commercial viability of our COVID-19 testing business, (v) changes to the biosecurity industry, including due to advancements in technology, emerging competition and evolution in industry demands, standards and regulations, and (vi) our ability to realize the expected benefits of merger and acquisition transactions. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of Ginkgo’s quarterly report on Form 10-Q filed with the U.S. Securities and Exchange Commission (the “SEC”) on November 14, 2022 and other documents filed by Ginkgo from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Ginkgo assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Ginkgo does not give any assurance that it will achieve its expectations.
GINKGO MEDIA CONTACT:
press@ginkgobioworks.com
GINKGO INVESTOR CONTACT:
investors@ginkgobioworks.com
RBC MEDIA CONTACT:
info@rbc.gov.rw or dg@rbc.gov.rw
View original content to download multimedia:https://www.prnewswire.com/news-releases/ginkgo-bioworks-announces-pathogen-monitoring-program-at-kigali-international-airport-301747236.html
SOURCE Ginkgo Bioworks
Company Codes: NYSE:DNA
